Stellar Drugs Ltd


BSE: 524612 | NSE: NA | ISIN: NA 
Market Cap: [Rs.Cr.] 4 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Indian - Bulk Drugs

 Discuss this stock

Company Profile

STELLAR DRUGS LTD. BRIFF HISTORY : Incorporated on 1st February, 1988 as a private limited company. Subsequently converted into a public limited company on 20th February, 1992. Promoted by Sanjeev Krishna Iddalgi, Madhav Mulgund and Smt. Neha Mulgund. Presently engaged in the manufacture of Trimethoprim and Atenolol with an installed capacity of 36 TPA and 12 TPA respectively. TECHNICAL ARRANGEMENTS : Entered iinto an agreement with Sanman Technical Services, Dombivli (East) for providing basic design, basic engineering, erection, supervision etc, for a total fee of Rs. 7 lakhs. COST OF THE PROJECT & FINANCE : The total cost of the project at Rs. 570.28 lakhs was to be met by equity capital of Rs. 456.57 lakhs, term loan of Rs. 91.24 lakhs and others of Rs. 22.47 lakhs. SCHEDULE OF IMPLEMENTATION : Commercial production expected to commence by August 1994. MARKETING ARRANGEMENTS : Has entered into a MOU with Merind Ltd. for exeport of raw material for a period of 5 years for a commission for 3% to 5% of the FOB value of Exports. Also entered into another agreement with M/s Chemox Chemical Industries Limited, Bombay for supplying raw material and to get 48 MT of Trimethoprim IP/BP88 per annum manufactured by the Company for a period of one year. RISKS AS PERCEIVED BY THE MANAGEMENTS : (i) Trimethoprim and Ibuprofen and their formulations are covered under Drug Price Control Order (DPCO), any increase in the cost of the prices by the Government would affect the profitability of the Company. (ii) In the absence of any stake of Financial Institution/Banks, deployment of the funds is entirely left at the discretion of the promoters, (iii) Consent of Pollutiion Control Board for expansion project yet to be obtained. (iv) The Company has outstanding dues towards instalments of principal and interest against term loan to Madhya Pradesh Audyogik Vikas Nigam. (v) The appraising agency is not participating in the means of finance. DETAILS OF THE ISSUE : Authorised capital of Rs. 500 lakhs comprises 50 lakhs equity shares of Rs. 10 each. 7,67,850 equity shares of Rs. 10 each issued, subscribed and paid up, 37,97,850 equity shares of Rs. 10 each, now being issued, of which tthe following shares are reserved for firm allotment: (i) 5,47,850 shares to promoter, Directors etc. (ii) 2,00,000 shares to Apple Mutual Fund. Of the remaining, the following shares are reserved for allotment on preferential basis: (i) 12,000 shares to employes; (ii) 4,50,000 shares to Indian Mutual Funds; (iii) 5,00,000 shares to NRI's (iv) 3,25,000 shares to Medi-caps Limited with a provision to add back unsubscribed portion, if any from the preferential quota to the public issue of 17,63,000 shares.

Related News

 
No Related News

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Lupin 49,055.98 21.27 7.03 12.61 39.3 49.4 0.07
Divi's Lab. 19,927.77 25.17 6.57 14.99 25.9 32.9 0.02
Jubilant Life 3,024.31 13.29 1.74 15.32 4.2 7.0 1.52
Shilpa Medicare 1,892.27 23.41 3.88 9.81 14.9 14.9 0.25
Vinati Organics 1,876.04 21.77 6.05 5.75 32.1 27.2 0.96
Suven Life Scie. 1,305.24 9.38 4.94 3.88 68.8 67.7 0.50
Granules India 1,287.53 15.89 3.74 5.09 11.7 13.3 0.76
Marksans Pharma 1,277.27 23.02 8.72 4.97 41.9 19.5 0.00
Dishman Pharma. 1,207.68 13.92 1.52 5.90 9.1 11.6 0.72
Sequent Scien. 1,050.49 0.00 26.14 0.00 0.0 0.0 2.06
Hikal 1,028.57 16.05 2.58 8.61 -2.5 5.0 1.57
Shasun Pharma. 983.02 27.90 2.77 9.51 9.6 8.3 1.17
Aarti Drugs 754.94 12.97 3.01 4.35 26.9 21.9 1.39
Nectar Lifesci. 629.16 10.13 0.68 4.00 10.4 12.8 1.16
Orchid Chemicals 547.04 0.00 1.12 16.79 0.0 0.0 3.31

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

S K Iddalgi , Chairman 

S K Iddalgi , Managing Director 

Nimesh S Joshi , Company Secretary 


Company Head Office / Quarters:
B-1-B Gokul Bldg,
80A Baroda Street,
Mumbai,
Maharashtra-400009
Phone :
Fax :
E-mail :
Web : http://
Registrars:

No data found

Fund Holding

 
Scheme Name No. of Shares
No data found

Calendar

Jul-2014
M T W T F S S
21 22 23 24 25 26 27
IPO
listIssue Closing : Bhanderi Infra.
Economic Events
list Cap Goods Orders Nondef Ex Air
list Cap Goods Ship Nondef Ex Air
Results
list Ashok Leyland | Century Textiles | Colgate-Palm. | Colgate-Palm.